Search company, investor...

Founded Year

2001

Stage

Series F | Alive

Total Raised

$135.03M

Valuation

$0000 

Last Raised

$69M | 16 yrs ago

About Pelikan Technologies

Pelikan Technologies is dedicated to the development of hand-held diagnostic and monitoring devices capable of improving the screening and management of a variety of medical conditions. In addition to diabetes, the company's versatile technology platform has applications across a range of other medical conditions that involve blood screening and monitoring. Point-of-care testing and diagnostic panel test systems also represent markets that can benefit from Pelikan's technology. The Pelikan Sun can improve the quality of life for people with diabetes by combining several of the company's technologies into the most convenient and effective blood glucose self-monitoring device available. Pelikan's line of diabetes management tools will address the pain and inconvenience that has stymied the industry's manufacturers, and plagued people with diabetes, contributing to poor blood glucose monitoring compliance. By targeting these barr

Headquarters Location

1072 East Meadow Circle

Palo Alto, California, 94303,

United States

650-842-1000

Loading...

Loading...

Pelikan Technologies Patents

Pelikan Technologies has filed 57 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/1/2004

9/11/2012

Springs (mechanical), Automotive suspension technologies, Surgical procedures and techniques, Surgical removal procedures, Implants (medicine)

Grant

Application Date

6/1/2004

Grant Date

9/11/2012

Title

Related Topics

Springs (mechanical), Automotive suspension technologies, Surgical procedures and techniques, Surgical removal procedures, Implants (medicine)

Status

Grant

Latest Pelikan Technologies News

Pelikan Technologies and Lilly form alliance to promote diabetes education

Feb 13, 2019

%PDF-1.4 %âăĎÓ61 0 obj > endobjxref61 170000000016 00000 n0000001027 00000 n0000000636 00000 n0000001302 00000 n0000001597 00000 n0000002178 00000 n0000002610 00000 n0000002990 00000 n0000003024 00000 n0000003266 00000 n0000003514 00000 n0000003590 00000 n0000006578 00000 n0000010765 00000 n0000013811 00000 n0000016503 00000 n0000000860 00000 ntrailer]>>startxref0%%EOF63 0 obj>streamxÚb```f``1c`a`ŕ˝ĆŔǀ |@1V ćX°Ë„a-DKxç2AĄĽű@löF‘ňŽ đËŇź@,QbŕĺĐč8,#ş€ŮAę€VL_xÇ2…&!F¨=œ! @š ˆ­€˜ƒ! @HĺYTŔƲßf 0 ­ďzendstream endobj 77 0 obj>/W[1 1 1]/Type/XRef/Index[14 47]>>streamxÚbbâ``b``Š Ŕ ;œ —endstream endobj 62 0 objE N - U S)/PageLabels 9 0 R/PageLayout/OneColumn/StructTreeRoot 14 0 R/Metadata 12 0 R/PieceInfo>>>/LastModified(D:20080415234148)/MarkInfo>>> endobj 64 0 obj>/Font>/XObject>/ProcSet[/PDF/Text/ImageC]/ExtGState>>>/StructParents 0>> endobj 65 0 obj> endobj 66 0 obj> endobj 67 0 obj> endobj 68 0 obj[/ICCBased 75 0 R] endobj 69 0 obj> endobj 70 0 obj> endobj 71 0 obj> endobj 72 0 obj>streamH‰|WŰrŰH}×WôŁ´%2$Eń˛55UŠ­Éx6žěXyؚهْ8ĄŮIŮŤýú=č)ÉŮJ9–i8 €ď“Ÿžśë&a”űAAą ˙âIJ ŒĺKƒÜĎĂ/“w/ť•“N>n&Vm_myŃłŸ~úů珷7Ěý°Ů,d›-Ě+Ťř…™ŸjƒŰźLŚlśůk˛žÇkëÍäű$Kü8ĎňÁ"dq´Ŕ{‰O8ň$7@ÂČ|¸żšťĹ{Éf^"X KňĽÄţGBkŔ|xĎŮŚ`ô)Z˛ÍóÂÔ_ÄK|÷CŸg^CZň| „ĘÜ/3o9}œy‹éď÷lĽßž›yátőpłf›Göôűăýăf=2HH´ÁPƒĆdńönőqM†6ëg2ĎÖˇ_nV˜MÉUʢBúIbĐ˝Ÿąh”ňHżî-ý|Šł/ü枊’‘OPŹsřŃ(ŐÓY×üŤly_ɆýZíö5žúŽ­ËcĄňŚdżTÍN;m+29Î6Š–ý*xÝďYհۊ˝čŘ=ořNźˆŚgďbŻ‰5$ɋ™Ź˙'ŕĺYŔ]ś0/śšLŸx-ŮŞîĺœÝŹTTwMYâAÖU7gwsś:´UÍÂdÎĐźšŐě'ΞĘgQă™BzěIÔŐ7Ţ°(öŹĺŽBîšÂŸ3ŽŔ+Ąą‘äšTjR^"ߏŻ˘–Ń2šE^ůŠ‚źśvo/꒕•6ŚQlK:Úó]#ťž*TŹ/łl*›Ş—-L+f*,K‡EŃ˙U!z]WC‰mô„Š ~Ółţ\ŐőI˝x#gÉôĺŔ›ëeÉéa#M!J ŻÜ:\T˛5đ“Đő ǡBx'Á[VHďĐJ(v’ ÔĎ2—šfňď}Ć.\áSšš`ÎBůҔ(íĹl9m_fů´#°ą†ŻĄĐS9§#Gƒă!35Z¤°Ě2p€Ţiސ?F"wp${ÁřoE#ş ŘuIBU‡+ű#üTáşýIţ()œ$Pu(~ę‡^•ŹoďřZE”A›ŞPoƒĽiů9ěőQѡjşc­ÝľüpšłŤjņ>ÚŕĐ öÍíô*ړe˘çzŤŕ5㼹ÇVřŁĽ+ý+ĎTt $ k°&™ýMő_ä §vPĎ ˛@ŁĺX>•.:í#xŸęc! ;Áî]łůď‹_âtËI^`-ßţ@ëŇ3­ł#*ѕßü ?‹zëő:•çk-eÉvZ…D˛oâ¤H—M˛1UŰ­(”ÄŘzžó„ŇŁŰÇä(Œ‚Áő“‡Z€šČÄđţąëY+vǚˇ‡lH˛Uě0ˇ¤˝ŔN§j/đפ‹ ÚŰž*ö0ţýXľpuŠŻAdô՘ľDŮň7“ÎĘVL’ĐY˛‡KÔhˇ@ŰÎźhŞň¤úfŔmIeĄÁƖw}uP]Ť:€­â 0“Ącß#Sšv@.8â iŹgÚú"ŒóÂx‚J3'BC"83Ł˘ĎÂ'm]…lŠ•ĐJ…¤4˘EűŒFőŞëHkŠJŠÄŸQuě@OşŠĚÎúÂAY[ýŽç˝m5†÷Ď=ځˇĽN(ÁźĽęŰh™Ţłv.fşn9‰†aŚqÂrBł9ăSŹů†FÜëO‰}7XćąÍerś ęĹĄźĘ‹ď‡÷čüćH暏°ŠżŒŘ˝dÇN‹ě’nęme­jţ˘6“ v{yŹő$ˆă´ŇžEhˇäĺxKžž×jB2ٞĂôěGZ=-F; kEÜMw_jOv­WŹ xŢUŹüz%ŮЃÄȆٙ5„FŤÓhÁˇ2-UžsL#Ť´`iĆZ[ĎÇFeŔ!Mý ‹úĺátÉS5“qśü-ÂË҆Q¤ÇÝpmĺ¤$x/ô—‰>wDRś´b4[hX]îJaćfĂJ"WƒJu5ć›l(ĘBǨ_*RŸöŒ&‡3Œ˝(uwŽM!Ů@žŢÁ֝:tŠ–N‹0\X‹§ŔŽ%{F2!1Zvl­ŔŢ&Hz˝żé˝… Ęś'łľ¸V1l—Nłđl7ŠkůfJü˙WXXő&|L('IGÉÉĆiŮ­DîůXěG4ą’Z•sœmŽ-ą-¨ ó¤?đËąL•ž„-DŤg[ٲ+Yěşnl /u‰Őln5ŁoőɃhЎ%c¤!×úaWŞĽăłYtŹ AL”6ź×ďÚ\‹™Ýˆ[äm˝ÍFbˆĘxÝIZg-˛T#‹ąž™Ćö$ ěî RŮS5ĚF‰”rx×ę6ň´ĄQÚdó*°ě˘ gö3"Ščuq:ž(ԑX5ÎęÂ-=–Ź#IălxÚňÝ}ÓóVpu^ŔĐ7XZœPŻ#žÚç7 Â3š‚píţJZií§yâQŕÔŔĂ~•hzZŞîţ‰Ľ•KđnŕTn=‰IqčŘ(*ÄÝuOź"ö­ž-TŽK1˘zäPťÓÍQH$jĹĄćčYšh’dŐ#‰ĎvŁF ĂKßMüKEƒłA _ů‘Áąô[ýÎFů§›}+ť˝á5” ˘ÂÍEÉčšöëů.üŘ$Ki>5;!ž‘0˜7Á†šačƒÍÁŮ´‡˛hĂeôőÄ.Y§z)ő˘ŘĎÎÖŻ–W‘ĘeDýşÚ˘QOőĎŤŤł –†ÇšcŔ|X8ú=EÜO•ZOˆf%鋣̎Kš˛z8XúnѢqŃBŰfÁ}ů‹ˆî“?Ś*íĒ=¨őU oĐżAŞQö†%›:/Ńm•ÚmL×+tŕO8ÜnöŐ%’]Ô`žĄ`4"ÎććŇĚÍHÍÍ콚™YgŠëńłą‰Iö"Z,ŔőhQƒúE‹šé¤Ž_0NJěˆb›0ČŹŽÇA(,˛ča}a1j‰qÓ4ňUŃnŽJŒł"Z}'ědw7)÷MOÇ,‘…@kţ•>^q.3Ý ľĂŞ#.Ń{ĐǓ™ ÷/¸Ůŕŕy–N{J-ďíďČ9BĽ:Ô稧͏ Ÿo}ÓŽtƒŇÜĄŹëzÁ˛ŠAÚłtćĹÓzԆšŻ‡–c§ŚÓ˘—˛Öôšiyœ"kXDd‚pD|'ď+§aăś8ƒĄîx Ý€\ďZN´ƒNÖÇžş^? ɊŃŇOÍQˆłˇÓ‹K}°ŁšVe?S'y$;˙Łťv„Ąŕ}ż˘°Y˘×UĆ‹‰‡Ý‹5T˜"‰ţ˝3ďŒR -óޛ7#ßËY{ś[KuˆÜl¨ÝÂ+tÖügB5őŒ°Gé,Ę{ÇŚČţVç9i,;•X”1?”ľ?Űű˘˜ôˆB;žLCče’Ĺ—›†PĎţi‘ˇ(ŮYK“ܐdx|•pƒ7DVŇĄ4=4˘A*5/U~^đNvžŤÎÁę^Ttá.ĚӀiŃoż#ôL e‰îÁKä(N—ĘŒ´ô˘ă¤5Żăi čvőŽŇˇüźM5ułUćvĂ. )›´ŞK>ŐS ĺ/N ÷#ŘV.tîDŔ慳DŇ,o6ÇX“8_ídČŹ3ąű=Ŕš…óGóSÚüČŮ*ZDčŃèn‰!ŮÖ)†ĺćă!Ŕ |üRÁendstream endobj 73 0 obj>stream˙Ř˙î Adobe d€ ˙Ű „$$''$$53335;;;;;;;;;; %% ## ((%%((22022;;;;;;;;;;˙Ŕ h ´" ˙Ä? 3 !1AQa"q2‘ĄąB#$RÁb34r‚ŃC%’Sđáńcs5˘˛ƒ&D“TdEÂŁt6ŇUâeňł„ĂÓuăóF'”¤…´•ÄÔäôĽľĹŐĺőVfv†–ŚśĆÖćö7GWgw‡—§ˇÇ×ç÷ 5 !1AQaq"2‘ĄąB#ÁRŃđ3$bár‚’CScs4ń%˘˛ƒ&5ÂŇD“TŁdEU6teâňł„ĂÓuăóF”¤…´•ÄÔäôĽľĹŐĺőVfv†–ŚśĆÖćö'7GWgw‡—§ˇÇ˙Ú ? őT’I%)$’IJI$’R’I$”¤’I%)$Ā &ä”óđmłŇŤ"Ť,ýĆ˝Ľßp)$D› [§I$’B’I$”¤’I%)$’IJI$’R’I$”¤’I%)$”-śşk}ś¸2şÁsÜt I)+vkŸęß^~ŻôÇ:łqÉšź×Gž›´hű×ő‡ëoTúřű3¤‡ˇÇlŽşô˛ď7ůy}ëkĄ˙ ‹ …×éXň9xG'=3H\păůţŹi˙ 5[MGŇĹ{ĂlľĎ—5¤ĆíĄ˝—v"F đŞaô~•‚ĐÜLJŠťX'ćîJ¸¤€˜ž9q}|ÖN^f?wÄq (ܸ¸ź|°ţ˛ýlŔ躌ĚxšąšuţłĎćľëÖĘz7ĽLYÔ.˘Źę?Ň?ËŔw\/Őߍ}GëV{óslxĆß9.úOwî2{ţ3&R5™ü\—! @ó;'ë_×,§WYséZÚK(Ź+Çç%cőžÔěÄu9Τ¤˜€ďiĐȕę=sŤôżŞ!¸ŘUą—š¤băŽIďcűljÉ~-6zš;ü%„îůO’‚xýB6eî{:źŻ9úŹ™Ž8ŕäńƹƽS?ËGÔ°]s°ąÝóΊ†ĎëßŠ:I+Ż0M’vľ$™:HRI$’”’I$Ľ$’I)I$’JRI$’”šń‹“mVŹmf={YSČýÓ. ?~ŐÓŞo¤ÓÖ:eÝ>ă´Z=ŻľăVťäSf Œ€Ü†nW$qó§?–ŒxßńW‡Šćć搒Âڛ Ż úĹő/Š›6O´¸‚ęngÇýH]VřÓéď`ؖÔ˙ Î5öĎö‹JƒXĆô‘ÝÔř—#Ÿ>cĚaý~SÜ,ŹżXqşO9Cď|ˇ™ŐÎóţHî˛_ţ3~Ž†Ë[ăŕĺzóÎż×2şçQ~fA†ýjÁĂGńNËĚDGŇnE‘řFl™AϏu xGĄtnĄőťŹY“–÷z;ˇĺä|xcëş××>őtތÖ_}-ŘĆ3ůŞ˙ ŹáôůŽC§QőˇŞaWÓzuVW€9•n'—YaÄüWOŃ˙ ĹçNé՜î˝snô†÷W;ihžL~E>:ô OÍ9~Ć÷;÷pg ”1鋕ï—Ďô_ŤgënsşŽ}n3Ý6仗GćT8ţzŽ'NÄŻąUkGâIîJKęÝ#¨0łŚ_]­¤ Y^›Gonš(uŢľ‹Ń:{órLÇśŞÇ/yáĄOŽ„LŽűÉĘç9žcšËG *ťXW[ë˝?˘bœœ×Á:WSu{σGń^wÖ­Ÿ[2݉ŇĂąńű˛Ł´5ž6ŰĎúđŞtüąőߏż#%ĺ´4ZßĚ­ŤŹxř}ĺm}gëÝ?ęţúťĐ eąˇ&ć™-Ÿ¤ť˝ÝĎe˛ƒ"L1ŽŰÉĐÁĘcĺç0„yŽrBäeŽ\ǀčŕţ¤tz6ŸXúźRvH,Źňň?yÜýëŤuţľőè›Óćb8űi%Łü%Îź¸K˝¨kfS>˜ŁœĂ÷Ţb c\źxrç:FúůÓÚćý{úł‡aŠŮ^łĆ‡ŃixÚ~+SĽől­Š2đ,őj$´čAœygÖ~…Ňú=MšŮ=UçÔČp1[47ĚřŽŰü]ôťp:śŕZüכƒOf@k>ř”üy&rČ ľŃŻÍň\Ž>R9ńNdĘ\1ăӏšłÔ¤’Jw%I$’JRI$’”’J6 ŞJ\rqÜí­ľ…ŢÂW”?¨uďŽ}gěußčÔňçWAqmlc|@úFŸâł¨ľ›ŠĎŠÖĹŽhŸë ߑ@3JVa :Ý:’řf\1ćy¨âÉ!|Uć_FśŞŽaŽć6Ć;–ńaőŞŸTEVeeáŐMu‚ë,iu`ßŘ@\ş—ÖߪYmÇşňG"§ź]S›ä&[ř.ťőŤŤ}e˛ŹM˘šIhn3ŁŹ:nsŻÂlłŔƒĹPýđü+™Œâqs `—¨ĺÇ"4ňhőCƒŸŐEŐCˆŽŠÁsŸaŸ¤wŕ˝3ęˇŐ.‚Ó•UwçŮśÇ4;iýĆŔŠÔ˙ ŠÔôJĆ^VŰşƒW [X?šĎ?ˇóşŽN ß›{(Źwy‰ň“ňG.œčÓ cř‡Ä^[–2–8čedË!üČlh€Š›őŤĽćôźÖZC\Zgk˜ŕá#ťI…Ĺýkúű‘Őě.›ťčű–X?ď­ňZßâçęČŞŚőܙő,b˛`}÷|{#î‰Ë‚#Š?¤|˙ ŁĺË`űÖiœYA‰Ĺ ,ńn8›żS>Śft,Ëłs/cŢö™]D‘‡8¸ËýhĎÉúĎő•˝?ӏKÍ4Iöˆţv×yi÷Ü}búŰŇ:V5Ő} YšXć×M^ç ş4lĺ/?¨ć7 _x-#vŮo.ÜOocˆă†˘ő&ďĂŁ—,ňóźĹBB8ç8Ô@­eôzŽŤőŤ¤töôŤ&CŰó‡.yŃĆż{îW>§}E~öu^´Íg}ŻÔ“Îűgň}ëcęÇÔ\ˇ+*2łĆĄä{+?Čż™ZÝWëGé5šŮ™,cŔŇ wX~l”řăÚyhVŃčššÁRĺů)Ë!ýfjź™ ޞü`őŹŽŁŐ+čRöR懱żŸ{¸oögďVÔzoÔ~˜p0ödőۚMƒVąßĘ> ěߙ\v.ORČę˙ hÂÜěü‹k-Őűě™Űy]×ŐĎń{V3†^sn¸{ţÎLą§™ąßœŠŠs”ĽŠý#´C{˜ÇËň¸1bÍ/ŐŔqPůłdţˇő\żŞT˛úŢ_펾šŘÎw¨ŸJ÷xŸä~Ué{Ťk›\€â=ŹĐÉr˝ë˙ JéŒv?Oۛ”4‡ôLţł‡? ¸~Ÿ‘×ţąýbŚĘň^Ü×:EŔŔŠƒS´áŠŁ\‰ŐŠ>W™ç¸łç#–ĂŽ'ی†€ĚžČ…‘“‹KŻÉą´ÔÍ]cČkGĚŹî­ő‹Śt,Psň=KĂ@ś ś9Ú8ŸšyĎPę˝{ëŻRn&;ikÇiö0~ýŽďńű”™3č=R;EĽÉü;&{œľ‚:Ë,´?vßZkšö‡°‡5ÂZŕd{‚¤˛ţŽtAĐúk0˝wä8Ďs‰Ú äVßÍjÔR XŁŮŠF3„¸â’ŞąŢ”’I"ąIˆAÔBt’Sç_ü\gӘrú á­Ýš•9ơ°žĚx쫟ŤßăćúVdÚĆš:~•éi(O/Иß@]ü_˜qǔÇA,š}Żœŕ˙ ŠüŰlő:ŚcXŽmR÷ŸížĺV:ˇřŽŠŢţ‘’XcZr5ů=Łř.ů$~ž˝P~/Ι‰{•_˘"8~ÇËéúŤő˙ zX×=•đy߸¸+8żâă­gZ.ë9Ąž0ău‡ćíôtź:’| ]/Œó&řcŽó„=_ź7]˙ řďÁĽ˝‘DúžŤŒÚj]Ŕ"ş`Őa?‘z‚I^ظůhŒćŁ pĺŁÄ%’ řź7I˙ t¸[ŐrKŸFŠc>núGđTzÇřˇę圞‡kMEۙSœYegÁŻî>kŃŇDŕÇUUăŐl~-Άg'ŠáôW“ćcęÇřÂČoĽvUŻƒż$‘˙ D¸ŤÝ;üW3xˇŞćËŤ¤Dül~ż‚ď’@rđërţń]?‹óD7żľţ/›uńoÔ¨Ë7ôG‡Ó;Ť­ĎŮegŔ8óŒĘ‡üÍúńÔ@Ť? (śžşňńŐné^˜’_w…őĐ>3̀D'(í9Fĺöź^'ř˛é´áÜŰîvFe•šľÚFÚëq80`ř•ÉfýXúĂő}Í˛ĆâąžÁuwm/ŸÍ`i3đ^ľ™™ƒ‹n^KĹtŇŇç¸řäůůÝWë§]e44†F=GčŐ_wżřŸ’41Äęčín|3šćóK$ňĚ\’Č4Ň;;Łô~Ł×ú€ÇǗ˝ŢëŻ|Ć÷sĘőރĐ0:ĆÄlźëuÎúow‰ňđ]Ąátâb‰ŕŠ“gYŸÄž%.f\ôŕŽĂ÷źOđRI$ŚsT’I$Ľ$’I)I$’JRI$’”’I$Ľ$’I)I$’JRI$’”’I$§Í?ĆO_~F`čÔ:)ƇdGçXD†üŢş¨˙ WŃş[nšżŻe€ű‰ĺ­:śż—5ˇ“Ó°2Č98Ő\AąŽ 2•q~°ÎFűx7˛óŔň˜ů\P8â5ČnřĎűęI$”­$’I)I$’JRKĺT’SőRKĺT’SőRKĺT’SőRKĺT’SőRKĺT’SőRKĺT’SőRKĺT’SőRKĺT’SőRKĺT’SőRKĺT’SőRKĺT’SőRKĺT’S˙Ůendstream endobj 74 0 obj>stream˙Ř˙î Adobe d€ ˙Ű „$$''$$53335;;;;;;;;;; %% ## ((%%((22022;;;;;;;;;;˙Ŕ ` " ˙Ä? 3 !1AQa"q2‘ĄąB#$RÁb34r‚ŃC%’Sđáńcs5˘˛ƒ&D“TdEÂŁt6ŇUâeňł„ĂÓuăóF'”¤…´•ÄÔäôĽľĹŐĺőVfv†–ŚśĆÖćö7GWgw‡—§ˇÇ×ç÷ 5 !1AQaq"2‘ĄąB#ÁRŃđ3$bár‚’CScs4ń%˘˛ƒ&5ÂŇD“TŁdEU6teâňł„ĂÓuăóF”¤…´•ÄÔäôĽľĹŐĺőVfv†–ŚśĆÖćö'7GWgw‡—§ˇÇ˙Ú ? őD’I%)$’IJI$’R’I$”¤’I%)$’IJIWČę]?ĆՓ“U6?čąďkIůŹAԒ”’I$ĽÓ'L’”’I$Ľ$’I)I$’JRI$’”’I$Ľ$’I)I$„rń[xÇuŹž+$n×É%%I$’R—7őţÇ×ИňÇzěŐ¤ƒĂźH…‘‹•_Ľ“S.ŽgcŔp‘ŢJx~ŇúÓú‡MĚâě\`Ö;&Ű/ŢŰ.pn㣇eÓç#;xe§hť-ŘÁ˛ç}}ßÁzmlelmu´1Œ 5 @ pŚî‡ŃžKŸƒCœă$šÚI'žÉ)ä˛ręĂúé†lżŃÄeÎë ŹMŔ{‰ƒńCú՛VOÖN•n%âÚ*‡Véi‹œ.ÎޑŇîpu¸”Řć€Ŕ\ƘktQŔLz/H.­ßcŚiţhěoˇ]ŢÝ4×T”ůý™˝VŹžžpœçCœ-;‰5Öl!Î`˙ X[ÝŠôΗőNÎŁMŽşđ"ďQŇ˙ \čÖA'O%Óׁ…U–YV=l}Óęš­ žu;źPbtpŇĎąQ´K}6Á#ƒ’Ÿ7ĆęY]>ÜN­ëßmćÇ? *§‡†mqĐ;ÚwVŻÖ&ÝŐţ°×Vď#]@kˆ!Žxńťťú~ĎuL˛?Fć‚Ý8Đř(UÓz}62ÚąŞe•ľ˝Ź ľşčaŞJxN‡Ö/ę_Y:YąďUIŚö’aÎcl÷ć!wšÇ$a^q 9"ˇz ńž=żŠ…}/ŚŐÚ*ĹŠ—É>ŤXĐ麲’ŸČuďžÇe‚ăę›'vîűĽwżâî΢ě+Űvă‚Ň>Ě]űÚďţJÝÎŔčyLvv=.źýŘŃîŽŰťüƒĆ02ś†ą˘Öˆ y •ŠŤÔđęÉĆw¨\ßH9íŘâÝ@ÖűŽŘŮáó]9Ŕ´‰B‚xŘőVęë­Ź­ßI­ :jrÇrđ˙ yp•y~ÖŘÚÝhkϨ=ďČ,p?2uDŤŇĚę™męw÷Ú\ZÓŕ@:oOP#Pv÷`áä;}ô2Ç~óš űÓ ĄóOˇ›É˛ŚôW7&ŰŘۚ7–ËO´&ęyDáa‹Ř*ŽŚöžK˝Łé.œâbš…&–†Ą›FŮř'łÖ5–TÇąŸA¤Á#„}U +ŒvęóJŹ‹şŽXĽîŚąkZ ×hlŠbu˛ş…š5ę}•Ä3ˇ¨ÖŽĹtÁi¸VŃk„Ŕ’>*5aâRýőRĘßĆć´ŕ˛xŹKsgö+ŒUWG•Ą¸–ôťňďČwۚă˛^wN‘¤÷OvVCŰÓ-žÇ&\IĐńü—JţÓ‹ý[1ęÝÉqhPČIt}ĽÔ‚ź´Ŕđ žÉćJóÖ짌v._Ö,ďQ¸íÇťőg¸‹ŸYtБägĽ‡ŐńYŇîsŮfŃkËÁ“ßäľwŐęëu;ŠôÜeĚkdđŽŤőwĹÔąŢ,Źƒ÷ÂR ĘĚă­uÔWej¨šŐ¸ffć}´›-Ź‘MłŇJ4'A@dô|şë6[ë€÷ď‰'萂пŹ}^˝űî¤ÚďŢ5‰üT?môYŠ¸§ÓtŃ[@$q:ŚÔuőÇôľęm:ţéčçĺ=˙ `é€8ű…’7ĎżšWś5?+mÄs‹ńq¸D l–Ęwuž†ö6ˇa’ĘçcKu1ŞUő·[^ĘđË[`‡€ĆAÇT‡?8ÚżV˝Žíž1,Ć}Íp’nÇśKőüć™ţ^ţ€űz—Ú˝@+/2áŽâi‘ĄěôËúNU˙ Şams564ü異ĽĂˆ ö[3ŽĘI$”Ť’I$Ľ$’I)I$’JRI$’”’IŇRÉ$’JA‡Vn3ńě;čŸv+Ż?Š`XęYsšk%Ľ‡ÜŮN]Âă~°Ö+ęśÇ熻ćFŞż2( Ú2c;‚٧ë^c`]S,óÓüUşţśbŸç({~;ű—2’€gČ:ߚóözÖýg釟P|[ýĹ?üćéź˙ óJäRNűĚü>Ä{qńzˇ}iéŔ{[cż˛ĺ*˝Ÿ[k˙ Žăćçů%s‰ yŒŔú'ۋąw֎ ˙ ćŰ]CČn?ŠĽoWęvýˆŃ“ěąć^÷(“ůT 'I5*I2t”¤’SŚ‹o°UK w )‚Őé]üŇ-şjĆńüçWű֟KúˇU1vl[o"žXߏŠŰ…g/Ögńc–NƒíGN5MŚ†1źüQIZىI$’JRI$’”’I$Ľ$’I)I$’JRI$’”’I$Ľ.7ë ‚ÎŤtpŔÖ}ÁvZÚj}ŻŃľ´¸ü •Ŕ]kŽľ÷?éXâăó2ŤóRôˆ÷6ɈjK’ITeRI$’”’I$Ľ$’I)I$—’JRKOęţ~T9íô*?œţOÁźŽ‡˘á`ØßRŃţúŸ—‚–'/ꏲ˜.Núť—•dN='Ç韀íó]6.~ž;gé;—‰GIZ†(ĂműąJDŠ$’R-RI$’”’I$Ľ$’I)I$’JRI$’”’I$Ľ'L’JRI$’œŻŹš>M5ƒî˝ÁŸ. ]ů"śţľßż.ŞŇŚn#ÍÇű‚ÄTsĘň ńŠš’I%ĺ$’v1Ď0Ɨ‰ü‰)d•Ú:/Tżčăš ÷´ŇZ8˙ Tďt‹šÁűŹŢa>8§-˘$DupQ(ĹÉÉvÚ*u‡ů#O™áu¸ßWşeMfçöü8Z-cĐÖ45Ł€,ySúFź–Ł yœOŞš‡eŘ*oî7Üᅤš‡Ňp0ŕÓXßţ‘Ţç}ĺ[IOPŽĂ^ĺa™*I$”‹T’I$Ľ$’I)I$’JRI$’”’I$Ľ$’I)I$’JRI$’”’I$Ľ$’I)ĆęWNn[ňNFÍń Ű0 őJżÎÉwÉŁűÖúJ3‡$‘żŠî9wpŰőO}+ŹwÂđGg՞–ŢZ÷˙ YÇřBŐI‹ýŽ9wiŐŃúe_G’;¸n˙ Ş•i•×X†40x4ůÓ'°m•$’HŠI$’JRI$’”’I$Ľ$’I)I$’JRI$’”’I$§˙Ůendstream endobj 75 0 obj>streamhޜ–wTTׇϽwzĄÍ0Ňz“.0€ô. QfĘ ĂMlˆ¨@DE €ŁĄHŹˆb!(¨`HPb0Š¨¨dFÖJ|yyďĺĺ÷Ç˝ßÚgďs÷Ů{Ÿľ. $O./– ™'ŕz8ÓW…GĐąý x€Ś 0Y銞AîÁ@$/7zşČ ü‹ŢHüžečéO§ƒ˙OŇŹTž Č_ÄćlN:KÄů"NʤŠí3"ŚĆ$ŠF‰™/JPÄrbŽ[䥟}ŮQĚěd[ÄâœSŮÉl1÷ˆx{†#bÄGÄ\NŚˆo‹X3I˜Ěń[ql2‡™ Š$ś8Źx›ˆ˜Ätńr p¤¸/8ćp˛âCš¤¤fóšqńş.KnjmÍ {r2“8Ą?“•Čäłé. )ÉŠL^6 ‹gţ,qmé˘"[šZ[Zš™~Q¨˙şř7%îí"˝řÜ3ˆÖ÷‡íŻüRę `̊jłë[Ě~ :ś w˙›ć! $E}kżńĹyhây‰RmŒ333¸–‘¸ żë:ü }ń=#ńvż—‡îʉe“tqÝX)I)B>==•ÉâĐ ˙ȉĺđ9 5ĘHÝ äç>€˘yPÜőßűćƒâ›Ś:ą8÷ŸýűŽp‰ř‘΍űçLg ů‹kâk Ѐ $Č t!0VŔ87°ř`ֈɀ2A.Ř@Řö‚JPęA#h'@8 .€Ëŕ:¸ î€`Œƒç`źóa!2Dä!UH2€Ě dšA>P ECqBšĐ¨*…*ĄZ¨ú:]€ŽBĐ=hš‚~…ŢĂL‚Š°2Ź ĂŘ ö†ƒá5pœçŔůđN¸ŽƒÁíđř:|ŸĂł@ˆ QCâ‚ř!H,ÂG6 …H9R‡´ ]H/rAŚ‘w(Š‚˘ŁQś(OTŠ…JCm@Ł*QGQí¨Ô-Ô(jő MF+Ą Đ6h/ô*t:]€.G7 ŰЗĐwĐăč7††ŃÁXaĚ:L1ć Śs3€ĂĚbąXyŹÖë‡ebŘě~ě1ě9ě vűGÄŠâĚp‡+Ç5áÎâq¸yź^oƒ÷ĂłńŮř|=ž?ŽŸ'Htv„`Ba3Ą‚ĐB¸DxHxE$ՉÖÄ "—¸‰XA %ž#ɐôI.¤H’´“t„tžtôŠL&k“Édy'š‘|‘ü˜üV‚"a$á%Á–Ř(Q%Ń.1(ńB/Š%é$šV2G˛\ň¤ä Éi)ź”ś”‹SjƒT•Ô)ŠaŠYiŠ´Š´Ÿt˛tąt“ôUéIŹŒśŒ›[&_ć°ĚE™1BŃ ¸PX”-”zĘ%Ę8CŐĄzQ¨EÔo¨ýÔYŮe˛Ą˛Y˛U˛gdGhM›ćEK˘•ĐNІhď—(/qZÂY˛cI˒Á%srŠrŽršBšVš;rďĺéňnň‰ňťĺ;ä) ô2*\R˜V¤*Ú*˛O(ŢW‚•ô••Ö)VęSšUVQöPNUŢŻ|QyZ…Śâ¨’ RŚrVeJ•˘jŻĘU-S=§úŒ.Kw˘'Ń+č=ô5%5O5ĄZ­ZżÚźşŽzˆzžzŤú# ‚C#VŁLŁ[cFSUÓW3WłYóž^‹ĄŻľOŤWkN[G;L{›v‡ö¤ŽœŽ—NŽNłÎC]˛Žƒnšnîm=ŒC/Qď€ŢM}XßB?^żJ˙†l`iŔ58`0°˝Ôz)oiÝŇaC’Ą“a†ałá¨ÍČÇ(ϨĂ腱Śq„ńnă^ăO&&I&ő&LeLW˜ć™v™ţjŚoĆ2Ť2ťmN6w7ßhŢiţr™Á2βƒËîZP,|-śYt[|´´˛ä[śXNYiZE[U[ 3¨F1ăŠ5ÚÚŮzŁőiëw6–6›6żŘÚ&Ú6ŮN.×YÎY^ż|ĚNݎiWk7bOˇś?d?â ćŔt¨sxâ¨áČvlpœpŇsJp:ćôÂŮęďÜćâVéöŘ]Ý=νŮ}ĆĂÂcÇyO´§ˇçnĎa/e/–WŁ×ĚŤëWôx“źƒź+˝Ÿřčűđ}ş|aßž{|ŽÔZÉ[Ůáüźüöř=ň×ńOó˙> ŕPđ4Đ407°7ˆÔô&Ř9¸$řAˆnˆ0¤;T242´1t.Ě5Ź4ld•ńŞőŤŽ‡+„sĂ;#°Ą łŤÝVď]=iY9´FgM֚ŤkÖ&­=%Ō:Ž‹nŠţŔôcÖ1gcźbŞcfX.Ź}ŹçlGv{ŠcÇ)ĺLÄÚŖĆNĆŮĹ퉛Šwˆ/Ÿćşp+š/jćý$.$…%ľ&㒣“Ońdx‰źž•”Ź”TƒÔ‚Ô‘4›´˝i3|o~C:”ž&˝S@ýLő u…[…ŁöUo3C3OfIgń˛ú˛őłwdOä¸ç|˝ľŽľŽ;W-wsîčz§őľ  1ş7jlĚß8žÉcÓŃ͉̈́›Č3É+Í{˝%lKWžrţŚüą­[›$řĂŰlˇŐlGmçnďßažc˙ŽO…ěÂkE&EĺEŠYĹמ2ýŞâŤ…ą;űK,KîÂěâíÚí°űhŠtiNéŘß=íeô˛Â˛×{Łö^-_V^ł°O¸o¤Â§˘sżćţ]ű?TĆWŢŠrŽj­VŞŢQ=w€}`đ ăÁ–嚢š÷‡¸‡îÖzÔś×iוĆÎ8ü´>´ž÷kĆ׍ E đŽŒ 7›§ŽEťůë7-†-ľ­´Ö˘ăŕ¸đřłoŁż:á}˘ű$ădËwZßUˇQÚŰĄöěö™ŽřŽ‘Îđ΁S+NuwŮvľ}oôý‘Ój§ŤÎȞ)9K8›vá\ΚŮóŠç§/Ä]ëŽę~pqŐĹŰ==ý—ź/]šě~ůbŻSďš+vWN_ľšzęăZÇuËëí}}m?XüĐÖoŮß~ĂęFçMë›]ËÎ:^¸ĺzëňmŻŰ×302tw8rxä.űî佤{/ďgܟ°é!úaá#ŠG叕×ý¨÷cëˆĺșQ×Ńž'AOŒąĆž˙”ţӇńü§ä§ĺލ“f“§§Ü§n>[ýlüyęóů邟ĽŽ~Ąűâť_é›Y53ţ’˙rá×âWňŻŽź^öş{Ööń›ä7ós…oĺß}Çx×ű>ěýÄ|ć쇊zť>yz¸ź°đ› ÷„óűendstream endobj 76 0 obj> endobj 1 0 obj>/Font>/XObject>/ProcSet[/PDF/Text/ImageC]/ExtGState>>>/StructParents 1>> endobj 2 0 obj[4 0 R 5 0 R] endobj 3 0 obj>streamH‰ŒW]ŰF|ׯ˜ˇŁM?DA ŰërH ,ŕ|÷0˘FŇŘ\R&‡Ú(żţŞçƒ¤¤ľspŕĐkłYÝ]]]ýmńć—O;ö‹˜—a´áQ”sáWš‡QEQ\°2b›¨Ë¸,˂łęyńć×çˆ=ľ‹-ŢmoŢvZDĽŮO?ýüóť§÷lúfťXĚś„7Qń?áĆälűźŘrűeńáwźöaťřś(ň0-‹˛äĽĹQ†#Jb–ňďĺ!á(ó҉' ŕÍďď}Â{Ɉ)ś­ž’˛dŰ6ĄBŽy™…qn ]dweňJišgşe;Ɇf/;-žŞćČôIőL=Ÿ[ü ŃßçcđÂ/BžfżÝ/>lŻÄNjŮ3š*ĄUŰ°J‹ŕ,ÔąY1ŐTő°ˇáĺrŁ.˙ÝţÓF.lä8Ą’˝°ľ˝ŽĂ8łáŐó˛, J˛öŔÎ]{–ŤńgŠ)š=;ŕ? :IQëӜÁ-ě2Ěb;XąĽOŹŞě"ęAějÉÎ˘Ó BQÔşmż˛ąŚŔk˙HPm¸jphťŃ™˛źě°.ʢŐEšXëť`ô. %aRxhŹMű“:[”żŠşž†˙á §f¤ˆ=)"“ą…gCNđ^}“oŹÄő9çŠůˇŸĐ|=ů(kőU4[ćAިoƒ49ŞŚi/Âä¨eujÚş=^Q@Řnř¸™ëCžřdŻT ‹ÚŁô˛=Ł&á‘R‚˝ˆ+UtěƒÇ˜ĺc(ڌ1¤/ˇć$YރŞŔgś]§Đ]b‘P CÇĘu4׉—Ę~%‹ä´ô„Ç‹ÄÉśQşíTłÜÇ%čcŞcťú&ăĚd´íT;ĐV^dźú1ŁŘӔ…Ď›%ô"ëšŢ Żś&čŕú2ˆî9jxXŚ2I`ú•aJ/Ԟ=wЇÉĆ7a{d˙–ZŤăŠ}řCVƒić“ęd…$W–ě—şÝ‰Ú#/J×Fšá}ňÝ{ׁ}Ȉ;o5ű XŐ2ă‡ÖčÎPŚ% 2H×7-.éÉʍGŠě41Ž:Ťš˝s‡h}ŁƒE‘šĘ7Rî{Óđ˝LŽśCkű‘iZW†ŕ/)đ$­ĽčGéüŇŞ†4čV$(hbä,Ţ̘nžě&ŘďéőFž˜ŻŒ*4ĆËGŕN7÷lW XlHl”ŔN˛>łšÎÔĆĚ5ÖÔXĎg&ŒTQAż´C×H'4ŻŠEňŠÎ˜`Ą2éliĹłĽ•LššL‚““ŕowí Çzm˝Ź(ŮÓfŰo„’›•—3ž@úR–Ľ v %˙üXٍřĽśw)6đĂÍŕ!˛ÜĆúźŠýÚT!ŤZęÄN5ř$QN=Řřč…ç4ś˛W”ÚoŠ3äIŹč]m$C˜ĺˇŒƒÚŻşI˘Ţ"KrĎ`9Ł˝ş$ˆx‚ u†lcđe‚7ăVďx˜ĽŁŢўÔBËu{Xƒ'kěH#›P4ęa›™ĺŮgprčԟ¤T†œô€Ä [ŁeôĂĺđ*NÝ ‰^z^rp}Orڞ!Žđj’ÔŤ]”ú|˛ąÜP}Ţ~AŮ#‘M )‘=vDM›çŘ´˝6jZ™’Óż€Ř/×E`˙H_U•„°MŔfń¸ÜŒŔłů`źť2ąßw˛ď˛+ČŽĎŞm.˛Q’,ν˜ dé(“&nlEߡ•d⌬TC×QŸĽ>ľVď,ƒl0˜ÂŇs1f9ÖCŐö´ś{Ź qş•;AÜ[ƒÎÁ“;´ľj':”I™§e12ŕ°š‹ş­ŕ5‰›ŢAÚ]OÔUmşyKˇ‚ăM2ZĂ"cGŃzŐkĘۧażŰËv^.ęŘvíĐ?LbźIKŇÉm`fŠŁŸ™mُü'pa@]`چ'âV9fś)5hHŐhX-yĚňŤî{Îžłd›­ąy‘+ÂŔ8Pý€‹yˆhôjśO†6VÔ5>žŸčä-M”fžĄô›‚>c—hC)_ĚC=P‡$¸M¸ëŐĎĆ=÷š˛|3Ń--ť5–š$h!ƒNҐĐs.BÁÇ DKŠ‰Žç úŤ0Š‡śúÇ.¤QjőgPۛü @“ą7숌܉łb˜*´•óór˘šZŰ;Wé™Ůő8ŠÂĚ˙öďřŢ>Ţ-ç)M:˛ƒ48ÂŔܞüx2ÜşĺŇ9OΧ=a}&q59Ř+y2˜čkŇ{Ąˇ÷ËÜ1YţÜv[÷ĆLÓ%EĹš’ľaýőăŒS—^fŁšłŞď•š@vĄQžK[_äĂGŠ•Zž†|Ţfˇ;ŤNĘĆËŔ0„ě#I:ęN‰Vł4/|q§đŇĎ ÄJpąĆQ˝‚Éú4źYŒľ9Ă\פ°šőWčaé‰SěnsŽý#%U„Ůća›ă2ÓĎ[SˇyPš:đtJŔŐ5ńNeýH=Łlřú-™{S“Ydž`ƒ’ŒÓÓw ŐćĆPqĎcwqĚ U’Ŕ7Z7őw„ľX´\o‚ÉĐâżŃo‘mńűv/xn›'ť(§eďfݍ3zqľ2BÓtśZ–kˆÜԓręÉ´=ł›žŘs€]Ěaƒ ěŃ ŔVć>7§MđűOŤz[ ˘6ó@_JĂ ÷WĂËKxśůĎ˝OHŇä;đaťˆÓN8Qí8{`‡ĂœurqXźŰÎťTN.ţ87ŇĄŰSŁx™a´XišžÚő8zĹޛÚáZ‰˝Ľ˙Ţm ńŕÂGç„ÔŢöőÇĺŇĎĎC@>ƒ3ËÍŻ+ž)ÓiM§´Ś?ŰLÂńŁkhmŽLEčóMÄ1~Wj#ݚUrGž‰vä#iߐʏ\´Š‰1{kĂĎ  ¤oiC!w˘>lŮÜÂ^›Đsšë¤řŞ~?h#švú‰Đ÷ž*ĘŻáe4NŠ9=1'ô:%XÓ`P9dˇÂQ)껋Ň`íJě•ň¤ ú4r‡[­3a`•?Šsëđ¤(źˆ—ńÍlĹ%O\ĹȜDÁ“™dŐě(óÁ=>/}Vn ńs׏"™€FĘÎŮđNœÝ-sŕlňÔ'"×l/@ÍÝŽqqćĐľ2őm#`ϔ1čŻuş&wڅgŮB+ÜĹľžŻ„NÂŘ6Ŕ;••Š%î)şędŒ jŠÚLŐ,˝},¸‡y[̙Ô_‹UkŽT¤íŽƒwhĚßj†íi=pP§ZÚô…5Úú$ćÂň$քž÷ýˇ˘mf.ˇ5J6‘ŕ˘~$˝qňí]߉/Ȝä3ő­ ďĆ˝î‚_!îNçtkNö;ş­ů…7IË0CÔż˙@xłď /Ăœg)˝ůôĆS3âű;Ć*đ‡Z9 #NžˇëôőĐ˙cź|w„Ą(ţ*MöeK„@Š”˝Á|ŒŃ‘(¸˘’ěéwîĽ-˙tYübĐ^ŕööœßŃEX Yn"˝ĂoHxqŽéLúQm›ˆ*Ď,>QR;źItŔF‹ąnp2, ˜nDݍk} Đ"ÎC´{íÄŃś=}lMŁ}¨mw– ‡Ü8ZOR)ZTžLç˜/W._ƞWq,ZBŃG%.ŤŰ•aŘ9‡†Ë…HCžob™1L—A$ „ř™uźž.QÓ˝ěDűX¨YLęѡö´ďë=Őţ¤ŽœI1mdŠczK}Í̇=fƒÓPšĘTOÚĘW!AđŇŽÄ%ç€ő¸Ź|›=ą7n)ƒë9ˇöhšú‡7ŸRZ,>0Mß7˜Ę"ÁvÍŢ÷Î4fĽmRşX“Ç:äŽ!€ ciźE,ůt{Gw¨#ôB=ce;EÂ;ń*ňd‰r#áX}PdjąĂŕ|`~VNTŚ€ŐľügŢR§ťI–ä™#ßâ=D2oă[ĎH,âfÔqC =Úľ0N>8Šňԋ˘“ÇÝ=ŇôĄ;ˆćn꣄ůC˙‚á• ocĽ–‚źb T…'’X§qń\‡˙Ŕ™Ň¤ ˆš ŮçB,“ą"Ö缀&l{˜d€ß)t+Qdąâ`ዠĎô] DöR`endstream endobj 4 0 obj>/Subtype/Link/A 7 0 R/StructParent 2>> endobj 5 0 obj>/Subtype/Link/A 6 0 R/StructParent 3>> endobj 6 0 obj> endobj 7 0 obj> endobj 8 0 obj>streamxÚ´V]oÚHݟrĽźě>lçŰR)!DɂT}@ś´7}0W3žçÜ33çV–$)GJjRŤHĹd%&˛6"•R”Ĥ%ĹIDZQŠd)-iƒá­%Ľ0Đ ŇcŕtęHǤL,I'¤Ź ™PÓ%dP-Bžřâ0žDY2ŕK€7AH řŇy Ü¤ˆą†^(C‘ MĹY ‰Đj!IGŠĐg!É$’PR;‰1¤ş8đEyŕ‹•!žuřÔqŕKĽ#ž4Ňä MbgœCŒ‘i‹rÁ– QĚĽXęDX‚î÷ďĹÝó܋a]-'ő]ĺý ,kŃ' i :łlą¸Îćá(¸ŸUžhňŠěÎÜřŻuĎ?“ƒrćPRNOQĺ*+Ś~¸ůűÓđżDodpXfŇ&`‘MP4ĂÁrp"Ěâ˜Ĺ1‹aĂ,†Yłf1Ěb˜E3‹Y&3Lf™Ĺ2‹fť ŮXôaĄf+†bč'ułÜ›˛zĘfÁ†áN´Ž#P1tů´É`óđFŁ7™Áꍲ`ö—ěŰe=Ëŕýpşů_.ëíům9Čé8ü'ƒ.óé˛ňâ˘*çlž—÷‹I•ĎW,ĂĺÜWŰwˇgx:x.9ÂçĺWq‘˙'>EY{”ĆĎ%,ś!˝ňťâ˛Ęž|“ž#źœpzúű}3ľőN^w“|Ő[ÚýŘi8îވˏűööüă@ÜŢ˙Kl´ţ”ˇ\°%K-ŻňâKăŔÝ^¸Ű7ßĂŃôě>řs,ÎÖďŻď‹á‹é^¨‚IŃţĎÁ~°A-j’ďdpÍğ=ÖžÚĎýcYy×YUoĽ?Íňi!>.uţřÜĚl%|Žň:/Ś×ĺƒWŐÝ=kĆ-„ŽîŻ•|Ý4Ë~­üÂOĘ*Ťó˛hśkŮ}Ů)ge5‚„ ƒÔ;9^mWźnڟnÖn'n‹éQŁ=]kWż[ťÜhWfí’ëÎ O÷‚äŽC_PdˇV¤Zî„n‰3-qś%ÎľÄE-qJ܇HV‡'”^ßXʎ)śÜŽŽoť›6|kC‘Źe[ł…}˛îXŕ[_tLůę {î-ď-’›Őwö.účŽ?t/w€ş-Đ´n5ý,Üľ˝#ŁśŔř{ýűťd•´-—śţ­‘Ş52؉ż´ýp_ďt÷żNwoóIóM€ *ŸĘendstream endobj 9 0 obj> endobj 10 0 obj> endobj 11 0 obj> endobj 12 0 obj>stream 3 PELIKAN TECHNOLOGIES CLOSES $29 endstream endobj 13 0 obj> endobj xref0 610000000000 65535 f0000016761 00000 n0000017056 00000 n0000017084 00000 n0000020303 00000 n0000020465 00000 n0000020630 00000 n0000020682 00000 n0000020748 00000 n0000021808 00000 n0000021842 00000 n0000021866 00000 n0000021924 00000 n0000025711 00000 n0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 f0000000000 65535 ftrailer>startxref116%%EOF

Pelikan Technologies Frequently Asked Questions (FAQ)

  • When was Pelikan Technologies founded?

    Pelikan Technologies was founded in 2001.

  • Where is Pelikan Technologies's headquarters?

    Pelikan Technologies's headquarters is located at 1072 East Meadow Circle, Palo Alto.

  • What is Pelikan Technologies's latest funding round?

    Pelikan Technologies's latest funding round is Series F.

  • How much did Pelikan Technologies raise?

    Pelikan Technologies raised a total of $135.03M.

  • Who are the investors of Pelikan Technologies?

    Investors of Pelikan Technologies include HBM Healthcare Investments, EDBI, Clarus, Heidelberg Innovation, Mannheim and 7 more.

  • Who are Pelikan Technologies's competitors?

    Competitors of Pelikan Technologies include BioIQ, Intuity Medical, Saladax Biomedical, STARR Life Sciences, InPhenix and 7 more.

Loading...

Compare Pelikan Technologies to Competitors

M
Meditsynskaya elektronika

OOO Meditsynskaya elektronika (Medical electronics) is engaged in production of portable devices (glucometers) for noninvasive (painless) monitoring of blood sugar content in human blood.

N
Neuro Diagnostic Devices

Neuro Diagnostic Devices, also known as NeuroDx Development, is a medical device company operating in the healthcare sector. The company's primary product is a non-invasive device used to detect fluid flow in implanted cerebrospinal fluid (CSF) shunts, aiding in the diagnosis and treatment of neurosurgical conditions. The company primarily serves the healthcare industry, specifically the neurosurgical market. It is based in Yardley, Pennsylvania.

T
Third Eye Diagnostics

Third Eye Diagnostics is a company focused on the development of non-invasive technologies for the evaluation of intracranial pressure, operating in the medical technology sector. The company's main product is a non-invasive intracranial pressure monitor that gathers information from the patient's eye, providing a single point reading of intracranial pressure, which can be used for diagnosing and monitoring conditions like traumatic brain injuries, stroke, and glaucoma. The company primarily sells to sectors such as hospital Neuro-ICUs, emergency rooms, surgical suites, medical transport vehicles, general practitioner offices, and sports events. It is based in Bethlehem, Pennsylvania.

Intuity Medical Logo
Intuity Medical

Intuity Medical is a company focused on simplifying and streamlining blood glucose testing for individuals with diabetes. The company's main product is an all-in-one blood glucose monitoring system that combines lancing, blood collection, and analysis into a single device, eliminating the need for separate lancets or test strips. This product is primarily targeted towards the healthcare industry. Intuity Medical was formerly known as Rosedale Medical. It was founded in 2002 and is based in Fremont, California.

h
hanse chemie GmbH

Hanse Chemie GmbH specializes in the development of specialty chemical additives and solutions within the domain of interfacial chemistry. The company offers a range of products that enhance the efficiency of industrial manufacturing processes and create unique products, focusing on effects such as defoaming, spreading, dispersing, and emulsifying. Hanse Chemie GmbH caters to various market segments, including agrochemicals, construction, plastics, packaging, e-mobility, and electronics. It is based in Redmond, Washington.

C
Cervimark

Cervimark is a medical diagnostics company that is developing a screening test for the prediction of pregnancies at high risk for preterm delivery. The test is based on quantifying biomarkers found in secretions of pregnant patients and correlating the resulting data to risk of pre-term labor. Proof of concept for this test has been demonstrated in a small human trial.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.